AKI Therapeutics A/S: Financial statements 2016
CVR: 37509736
Source: annual report 2016, Danish Business Authority
01/03/2016 – 31/12/2016
AKI Therapeutics A/S (CVR 37509736) has filed annual accounts for 2016. In 2016, the company reported a gross profit of DKK -6,649 and a net result of DKK -7,564. Equity in the 2016 report amounted to DKK 42,436. The solvency ratio was 88%.
- Gross Profit
- DKK -6,649
- Profit/Loss
- DKK -7,564
- Equity
- DKK 42,436
- Total Assets
- DKK 48,250
Official annual report
Find more companies like AKI Therapeutics A/S
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2016
As of April 28, 2016, KALLERMANN REVISION A/S STATSAUTORISERET REVISIONSFIRMA has been appointed auditor of AKI Therapeutics A/S.
As of April 28, 2016, Torsten Bjørn is registered as director of AKI Therapeutics A/S.
As of April 28, 2016, Peter Andreas Stakemann has stepped down as director of AKI Therapeutics A/S.
On April 28, 2016, the company changed its name from ApS STM nr. 4310 to Renoguard ApS.
As of March 1, 2016, Peter Andreas Stakemann is registered as director of AKI Therapeutics A/S.
AKI Therapeutics A/S was founded on March 1, 2016.
About AKI Therapeutics A/S
AKI Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2016. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named AKI Therapeutics ApS and Renoguard ApS. The management consists of Sigbjørn Georg Nielsen Kjærgård. The board consists of Charlotte Pahl, Christian Vinding Thomsen and Lars Otto Uttenthal. The company's owners include NIELS ERIK JESPERSEN HOLDING ApS, Beier Holding ApS and FINANSMANAGEMENT ApS. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -1,593,852,000 compared with DKK -1,960,091 the year before. Equity in the 2025 report amounted to DKK 551,898,000.